Antiviral Ensitrelvir Cuts Household COVID Transmission Risk by More Than Half
A phase III trial shows ensitrelvir slashes COVID infection risk in household contacts, with potential use in nursing homes.
Summary
A large randomized trial published in the New England Journal of Medicine found that the oral antiviral ensitrelvir dramatically reduces the risk of catching COVID-19 from an infected household member. Among contacts who took the drug within 72 hours of exposure, only 2.9% developed confirmed COVID within 10 days, compared to 9% in the placebo group — a reduction of more than 68%. No antiviral is currently FDA-approved for this use, but Shionogi has submitted ensitrelvir for approval as post-exposure prophylaxis, with a decision expected in June 2026. Researchers highlight particular promise for high-risk congregate settings like nursing homes and chronic care facilities.
Detailed Summary
For the first time, a rigorous phase III clinical trial has demonstrated that an oral antiviral can meaningfully protect people from catching COVID-19 after household exposure. This matters for longevity-focused individuals and caregivers, especially those protecting older or immunocompromised family members in shared living environments.
The SCORPIO-PEP trial enrolled 2,387 household contacts of confirmed COVID-19 patients across five countries. Participants who tested negative for SARS-CoV-2 were randomized within 72 hours of the index patient's symptom onset to receive either oral ensitrelvir or placebo. The primary endpoint was lab-confirmed, symptomatic COVID within 10 days.
Results were striking. In the modified intention-to-treat population, only 2.9% of ensitrelvir recipients developed COVID compared with 9% of placebo recipients — a greater than 68% relative risk reduction. Even in the full ITT population, infection rates were 4.4% versus 10.2%, still highly statistically significant. Earlier COVID antivirals Paxlovid and molnupiravir failed to show significant protection in similar post-exposure prophylaxis trials, making ensitrelvir's success notable.
For health-conscious adults, this finding has real practical implications. Ensitrelvir is already approved in Japan both as a treatment and as post-exposure prophylaxis. The FDA is expected to issue a decision on U.S. approval in June 2026. Lead researcher Frederick Hayden emphasized the drug's potential usefulness in nursing homes and chronic care facilities — settings where COVID remains a serious threat to older, vulnerable populations.
Caveats include the fact that the study population was relatively young on average (mean age 42), limiting direct extrapolation to elderly individuals. The article is a news summary and the full dataset warrants review. Regulatory approval is still pending in the U.S., so availability remains limited outside Japan.
Key Findings
- Ensitrelvir reduced household COVID infection risk by over 68% versus placebo in a phase III trial.
- Only 2.9% of ensitrelvir users developed COVID within 10 days, compared to 9% on placebo.
- No COVID antiviral currently holds FDA approval for post-exposure prophylaxis; decision expected June 2026.
- Paxlovid and molnupiravir previously failed to show significant protection as post-exposure prophylaxis.
- Results suggest potential effectiveness in high-risk settings like nursing homes and chronic care facilities.
Methodology
This is a news report by MedPage Today summarizing a phase III randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine, a top-tier peer-reviewed journal. The trial enrolled 2,387 participants across five countries with a clearly defined primary endpoint. Source credibility is high.
Study Limitations
The news article does not provide full safety and adverse event data, which are critical for clinical decision-making. Mean participant age of 42 limits generalizability to elderly populations most at risk for severe outcomes. The article is a summary; the full NEJM publication should be reviewed for complete methodology and subgroup analyses.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.